Aspire Biopharma Holdings (ASBP) Interest Expenses (2024 - 2026)

Aspire Biopharma Holdings (ASBP) has reported Interest Expenses for 3 consecutive years, with $1.6 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, Interest Expenses rose 450.24% year-over-year to $1.6 million in Q1 2026; TTM through Jun 2026 was $9.3 million, a N/A change from a year earlier, with the FY2025 full-year figure at $8.5 million, up 8606.45% from the prior year.
• Interest Expenses was $1.6 million for Q1 2026 at Aspire Biopharma Holdings, down from $6.2 million in the prior quarter.
• Over five years, Interest Expenses peaked at $6.2 million in Q4 2025 and troughed at $183310.0 in Q1 2024.
• A 3-year average of $1.7 million and a median of $1.0 million in 2025 frame the typical range for Interest Expenses.
• Across the five-year window, Interest Expenses surged 58.16% in 2025 and surged 450.24% in 2026, its largest moves.
• Over 3 years, Interest Expenses stood at $183310.0 in 2024, then surged by 3300.47% to $6.2 million in 2025, then tumbled by 74.41% to $1.6 million in 2026.
• The last three Interest Expenses figures came in at $1.6 million (Q1 2026), $6.2 million (Q4 2025), and $1.5 million (Q3 2025), per Business Quant data.